Therapeutic Efficacy and Safety of Sitagliptin, Dapagliflozin and Lobeglitazone in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Glimepiride and Metformin.
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Dapagliflozin (Primary) ; Lobeglitazone (Primary) ; Sitagliptin (Primary) ; Glimepiride/metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Triple3
- 09 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 09 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jan 2018.
- 10 Jun 2017 Biomarkers information updated